Skip to main content
CBIO logo

CBIO · Crescent Biopharma, Inc.

Track CBIO — free
$13.00 +0.09 (+0.70%) At close · Nov 20
Market Cap
$505.64M
Shares
38.90M
Volume · Nov 20 422.38K Avg daily vol (3M) 358.97K

Price & Indicators

 

Key stats

Close
$13.00
Fri 20 Nov
Open
$12.55
Fri 20 Nov
Average volume, 30 days
246K
shares a session
Short interest
4.2M
10.7% of shares · 16.3 days to cover
Day range
$12.53$13.30
Open $12.55 Close $13.00
52-week closing range
$8.94$26.98
Close $13.00 51.8% under the high
Short volume, last session
60%
Last earnings
May 26, 2026
Latest filing
10-Q · Nov 12
Price history
Jan 2020 to Nov 2026

Up next

Jan 25, 2027 Est · unconfirmed · in 9 wks

Latest documents

2026
Nov 18
Investor event
Nine INDs cleared with Colune; Phase III planned early 2028

Crescent Biopharma said it has cleared nine INDs with partner Colune Biotech this year. It expects over 2,000 patients dosed across its portfolio by the middle of next year. It plans to start the first of multiple Phase III studies in early 2028.

3 source passages
We have cleared nine INDs between ourselves and Colune Biotech, our partner, over the course of this year, by the middle of next year, we'll have over 2,000 patients dozed across the entire portfolio. We put out a press release set by early 2028, where I'll start the first of our multiple phase three studies. Open the document at this passage
Nov 18
Investor event
Three programs dosing; nine INDs cleared with Colune Biotech

Crescent Biopharma said three of its programs are now dosing patients in the clinic, and it has cleared nine INDs with partner Colune Biotech this year. It expects over 2,000 patients dosed across its portfolio by the middle of next year, and plans to start the first of multiple Phase III studies by early 2028.

4 source passages
We have three programs we brought into clinic this year, all now dosing patients, and we can talk more about some of the milestones associated with those. We have cleared nine INDs between ourselves and Colune Biotech, our partner, over the course of this year, And we really are executing on our global strategy to deliver on combination therapies for patients that are living with oncology. And, you know, like we said, by the middle of next year, we'll have over 2,000 patients dozed across the entire portfolio. We put out a press release set by early 2028, where I'll start the first of our multiple phase three studies. Open the document at this passage
Nov 12
Current report 8-K
CR-001 dose escalation completed; cash runway extends into 2028

Crescent Biopharma completed Phase 1/2 ASCEND dose escalation after dosing more than 125 patients and plans initial CR-001 monotherapy data in Q1 2027. Cash was $289.4 million as of September 30, 2026, funding operations into the second half of 2028.

Financial results
3 source passages
Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination expansion cohorts; on track for initial monotherapy data, including antitumor response for first-line non-small cell lung cancer (NSCLC) cohort in Q1 2027 Cash and cash equivalents were $289.4 million as of September 30, 2026 which includes the $133.4 million in net proceeds from the July 2026 public offering. Crescent expects that its existing cash and cash equivalents will fund operations into the second half of 2028. Waltham, Mass., November 12, 2026 – Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the third quarter ended September 30, 2026 and recent business highlights. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
APOLLO launched; nine-month loss reaches $85.8 million

Crescent Biopharma, Inc. initiated the global Phase 1/2 APOLLO trial in the fourth quarter of 2026 and reported a nine-month net loss of $85.8 million. Cash was $289.4 million as of September 30, 2026.

Revenue $3.12M Net loss $37.73M
Read from the MD&A section
4 source passages
As used in this Quarterly Report, unless the context suggests otherwise, “we,” “us,” “our,” “the Company,” “Crescent Biopharma, Inc.,” “Crescent,” “GlycoMimetics, Inc.,” “GlycoMimetics,” refers to Crescent Biopharma, Inc. and its consolidated subsidiaries, including Crescent Biopharma Operating Company LLC, taken as a whole. In October 2026, CR-002 received allowance to proceed under an Investigational New Drug Application (“IND”) from the FDA, and we initiated the global Phase 1/2 APOLLO trial in the fourth quarter of 2026 in patients with advanced solid tumors, including NSCLC, head and neck squamous cell carcinoma, and various gastrointestinal and gynecological tumors. We incurred a net loss of $37.7 million and $85.8 million for the three and nine months ended September 30, 2026. As of September 30, 2026, we had cash and cash equivalents of $289.4 million. Open the document at this passage
Nov 10
Investor event
CR001 data planned for Q1-2027

Crescent Bio plans Q1-2027 safety and tolerability data from 125-plus CR001 monotherapy patients, plus ORR results for up to 12 frontline non-small cell lung cancer patients against a 50 percent benchmark.

5 source passages
Crescent Bio, we have Josh Brown, the CEO. So we have released a press release on our progress a couple of weeks ago that we have dosed more than 125 patients of monotherapy CR001 in the study. So with regards to the data package that we are working on to release in Q1-2027, includes safety tolerability coming from 125-plus patients of various tumor types and per-dose level. In terms of anti-tumor activity that you were alluding to, we will be focusing on up to 12 patients of frontline non-small cell lung cancer patients. And so our benchmark will be 50 percent, again, coming from Harmony2 study. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$15.00M
Trailing 12 months
Net income (TTM)
−$109.15M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-1,216.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-16.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$289.36M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+180.0%
Year over year · more shares
Price change (1Y)
-0.6%
Trailing year
Short interest
10.7%
Latest settlement · 16.3 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −19%
below
Price vs 50-day avg −8%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 23%
mid-range
Momentum
relative strength
Weak
1-month return +1%
trailing
6-month return −24%
trailing
YTD return +10%
this year
Relative strength −14%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $14 › 200d $16 — 200d above 50d
Institutional flow Accumulating
+31% holders QoQ · +37 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.70% of shares out · ▼ -5.8% MoM · 16.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
105 holders — near 1-yr high, broad support
Squeeze score 77
high risk · 0–100
Fundamentals
Poor
Revenue growth −100%
Y/Y
EPS growth −2%
Y/Y
Free cash flow $-72.5M
Quant / Vol
risk profile
Very High
Volatility 82%
annualized · 1-yr
Max drawdown −56%
past year
ATR 8.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−19% Bearish
Price vs 50-day avg
−8% Bearish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
23% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $14 › 200d $16 — 200d above 50d
Institutional flow Accumulating
+31% holders QoQ · +37 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.70% of shares out · ▼ -5.8% MoM · 16.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
105 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $9 Now $13 · 23% Range high $27
vs 200-day avg -19% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
IND clearances achieved by partnership 9 this year —
Ordinary shares and ordinary share equivalents outstanding 44.1M As of September 30, 2026 —
Patients dosed in ASCEND trial 125 as of the release date (more than 125 patients dosed) —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CBIO
Crescent Biopharma, Inc.
this stock
$505.64M +9.6% -99.9% — 10.7%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
105
% held
103.9%
Net QoQ
+11.3M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
22
View
Short & Settlement
Short Interest Falling
Shares short
4.2M
Days to cover
16.3d
Change
-258.4K sh
View
Short Volume
Short vol %
60%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
130
Value
$1.8K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
35.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$10.8M
Net income (FY)
$-153.9M
EPS diluted
$-59.00
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
26

Crescent Biopharma said three of its programs are now dosing patients in the clinic, and it has cleared nine INDs with partner Colune Biotech this year. It expects over 2,000 patients dosed across its portfolio by the middle of next year, and plans to start the first of multiple Phase III studies by early 2028.

View
Proposed Sales
Value
$8.5K
Shares
4.3K
Filed
May 17, 2023
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Crescent Biopharma Reports Third…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
CBIO -8.1% +1.4% -23.6% -3.6% +9.6%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +0.4% +10.6% -14.4% +5.2% +8.5%

Capital returns

Latest dividend
$24.00 / share · ex Jan 13, 2023
Cut 83.2%
Paid (TTM)
$0.00 / share · 0 payouts
Dividend yield (TTM, derived)
— · no payout in the trailing year
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1253689 CUSIP G2545C104 13F (30d) 102 filings 99 filers Visit website Investor relations